Carlo CocuzziAI Expert, Pod Cast Host, Real Estate Investor and Funding Specialist

Are We Already at 70% Longevity Escape Velocity?

19 Aug 2026 · 1 min

Watch on YouTube

0:50

In this brief excerpt, two speakers discuss the emerging view of glucagon‑like peptide‑1 (GLP‑1) drugs as the first true longevity therapeutics. Speaker A highlights that many consider GLP‑1s the inaugural longevity drug and notes their massive commercial success, possibly making them the highest‑grossing medicines ever. Speaker B performs a back‑of‑the‑envelope analysis (with a disclaimer that it is not medical advice) suggesting that third‑generation, and perhaps fourth‑generation, GLP‑1 compounds could produce a substantial spike in Longevity Escape Velocity (LEV). Citing recent studies on third‑generation GLP‑1s, they estimate that a subpopulation of participants may already be experiencing around a 70 % LEV increase solely from GLP‑1 therapy, urging listeners to conduct their own independent calculations.

Chapters

GLP-1s are the first longevity drug in a lot of people's opinions, and it's one of the biggest-grossing drugs, if not the largest one in human history.
Bit of back-of-the-envelope calculations. This is not medical advice. GLP-1s, especially 3rd and maybe 4th generation GLP-1s, may actually be— when I refer to LEV, longevity escape velocity, as being potentially spiky, a pretty big spike. There have been studies done recently on some of the 3rd generation, if memory serves, GLP-1s that suggest at least some subpopulation of humans that have undergone GLP-1 studies may be at something like 70% LEV just with GLP-1 therapy. So if that is the case, and again, encourage folks to do their own independent back-of-the-envelope analysis, that's a heck of an LEV spike in a subpopulation that's being administered GLP-1s.